2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theFilgrastim Biosimilars Market?

An upsurge in neutropenia prevalence is forecasted to amplify the growth of the filgrastim biosimilar market in the future. Neutropenia is a condition characterized by a deficiency of neutrophils, a significant type of white blood cell responsible for fighting infections. Filgrastim biosimilars function to increase the production of neutrophils in the bone marrow, thereby boosting the neutrophil count to aid in infection combat. For example, as stated by the US-based biomedical literature database, the National Center for Biotechnology Information, in August 2022, the incidence of neutropenia was 0.38% among Mexican-Americans, 0.79% among whites, and 4.5% among black participants. Consequently, the escalating incidence of neutropenia is fueling the expansion of the filgrastim biosimilar market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

#What is the Anticipated CAGR of theFilgrastim Biosimilars Market, and What Factors Will Drive It?

In recent times, the filgrastim biosimilars market has seen substantial growth. The market, which will climb from $0.92 billion in 2024 to $0.98 billion in 2025, is expected to enjoy a compound annual growth rate (CAGR) of 6.9%. Factors that have contributed to growth in the past include expansion in emerging markets, rise in patent expirations, governmental measures, heightened healthcare expenditure, reduced biosimilar costs, a robust drug pipeline, and increased expenditure on biopharmaceutical research and development.

Over the next several years, a robust expansion is projected for the filgrastim biosimilars market, which is expected to be valued at $1.21 billion by 2029, registering a compound annual growth rate (CAGR) of 5.4%. This growth is due to factors such as the aging populace, and increased access to healthcare. The forecast period is set to see key trends such as massive investment in research and development for the generation of innovative and effective biosimilars, manufacturing biosimilars for the treatment of neutropenia to enhance revenue, and a growing emphasis on M&A strategies to spur growth.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4016

Which Upcoming Market Trends and Innovations Are Set to Influence theFilgrastim Biosimilars Market’s Path Forward?

Leading businesses in the filgrastim biosimilar market are pioneering novel products employing cutting-edge techniques such as recombinant DNA technology for biosimilars production. This method entails forming hybrid or chimeric DNA by integrating a foreign chain into an organism’s DNA. For example, in May 2023, Amneal Pharmaceuticals, renowned US-based pharmaceutical firm, introduced FYLNETRA (pegfilgrastim-pbbk) in the US market, a biosimilar to Amgen’s NEULASTA, prescribed for febrile neutropenia prevention and treatment. It aids in the growth and specialization of neutrophils descending from specific precursor cells, encourages their advancement, and enhances the survival and effectiveness of fully matured neutrophils, causing dosage-dependent increases in neutrophil counts. The introduction of Fylnetra marks the onset of a new batch of cost-effective medicines, promoting accessibility for patients, care providers, and payors.

Who Are the Dominant Market Players Pushing the Boundaries of theFilgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilars market include Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Pfizer, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Fuji Pharma, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratórios

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

What Are the Core Segments of the Filgrastim Biosimilars Market, and How Do They Contribute to Growth?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=4016&type=smp

What Regions Are Dominating the Filgrastim Biosimilars Market Growth?

North America was the largest region in the filgrastim biosimilar markets market in 2024. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2025, By The Business Research Company:

IVF Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ivf-services-global-market-report

Fertility Treatments Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report

Robotic Surgery Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/robotic-surgery-services-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: